NOVONIX Ltd Files 6-K Report
Ticker: NVNXF · Form: 6-K · Filed: Oct 9, 2024 · CIK: 1859795
Sentiment: neutral
Topics: disclosure, foreign-private-issuer, reporting
TL;DR
NOVONIX files 6-K, confirms 20-F annual reports, includes ASX announcement.
AI Summary
NOVONIX Ltd filed a Form 6-K on October 9, 2024, reporting information for the month of October 2024. The filing indicates that NOVONIX is a foreign private issuer and will file annual reports under Form 20-F. The document includes an Exhibit Index, with Exhibit 99.1 being an ASX Announcement.
Why It Matters
This filing provides routine updates and disclosures for NOVONIX Ltd as a foreign private issuer, which is important for investors tracking the company's compliance and reporting activities.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves as a notification and does not contain significant new financial or operational information.
Key Players & Entities
- NOVONIX Ltd (company) — Registrant
- October 9, 2024 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
- ASX Announcement (document) — Included Exhibit
FAQ
What type of filing is NOVONIX Ltd submitting?
NOVONIX Ltd is submitting a Form 6-K report.
What is the filing date of this Form 6-K?
The filing date is October 9, 2024.
Does NOVONIX Ltd file annual reports under Form 20-F or 40-F?
NOVONIX Ltd indicates it files annual reports under cover of Form 20-F.
What is included in the Exhibit Index of this filing?
The Exhibit Index includes Exhibit 99.1, described as an ASX Announcement.
What is the principal executive office address for NOVONIX Ltd?
The principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.
Filing Stats: 195 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2024-10-09 09:14:04
Filing Documents
- nvx-6k-oct-24-10-09_icon.htm (6-K) — 18KB
- nvx-ex99_1.htm (EX-99.1) — 34KB
- img58969013_0.jpg (GRAPHIC) — 96KB
- 0000950170-24-113633.txt ( ) — 185KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: October 9, 2024